CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...

CENTOGENE Reaches 12,500 Patient Milestone in World’s Largest Observational Study on Parkinson’s Disease Genetics Working together with Denali Therapeutics to accelerate data-driven precision medicine for the PD community Rostock International Parkinson's Disease (ROPAD) Study aims to characterize the genetics...

ClearPoint Neuro, Inc. Congratulates BlueRock Therapeutics on First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson’s Disease SOLANA BEACH, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...

CENTOGENE Extends Global Parkinson’s Disease Study Providing patients with genetic testing designed to accelerate the diagnosis and personalized treatment of Parkinson’s disease (PD) The Rostock International Parkinson's Disease (ROPAD) Study aims to...

The Benchmark Company Announces Closing of Public Offering of $5.0 Million for Hoth Therapeutics, Inc. NEW YORK, May 28, 2020 (GLOBE NEWSWIRE) -- The Benchmark Company announced the closing on March 27th of an Underwritten Public Offering for Hoth Therapeutics, Inc. (NASDAQ: HOTH) of 1,818,182 shares...